Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 65-77

  Walczak, Mateusz ^a   De Mare, Arjan ^a   Riezebos Brilman, Annelies ^a   Regts, Joke ^a   Hoogeboom, Baukje Nynke ^a   Visser, Jeroen T ^a   Fiedler, Marc ^b   Jansen Dürr, Pidder ^b   Van Der Zee, Ate G J ^a   Nijman, Hans W ^a   Wilschut, Jan ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Cervical cancer; CTL; Heterologous prime boost; Human papilloma virus; Immunization; Semliki forest virus; Virosome

Indexed keywords

CANCER VACCINE; PROTEIN E6; PROTEIN E7; RECOMBINANT SEMLIKI FOREST ALPHAVIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIROSOME VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HAMSTER; HETEROLOGOUS PRIME BOOST IMMUNIZATION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPLICON; REVIEW; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE SUBPOPULATION; VIRAL GENE DELIVERY SYSTEM;

ALPHAVIRUS; ANIMALS; CELL LINE; CRICETINAE; FEMALE; FLOW CYTOMETRY; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPLICON; REPRESSOR PROTEINS; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VIROSOMES;

EID: 79952939538     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp1002043     Document Type: Review

References (70)

1. Woodland, D. L. Jump-starting the immune system: primeboosting comes of age. Trends Immunol. 2004, 25, 98-104. (Pubitemid 38167491)
2. Lu, S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009, 21, 346-351.
3. Ranasinghe, C.; Ramshaw, I. A. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev. Vaccines 2009, 8, 1171-1181.
4. Radosevic, K.; Rodriguez, A.; Lemckert, A.; Goudsmit, J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev. Vaccines 2009, 8, 577-592.
5. Irvine, K. R.; Chamberlain, R. S.; Shulman, E. P.; Surman, D. R.; Rosenberg, S. A.; Restifo, N. P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 1997, 89, 1595-1601. (Pubitemid 27479719)
6. Ramshaw, I. A.; Ramsay, A. J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 2000, 21, 163-165. (Pubitemid 30184783)
7. Robinson, H. L. Prime boost vaccines power up in people. Nat. Med. 2003, 9, 642-643. (Pubitemid 36749205)
8. Harari, A.; Bart, P. A.; Stohr, W. F.; Tapia, G.; Garcia, M.; Medjitna-Rais, E.; Burnet, S.; Cellerai, C.; Erlwein, O.; Barber, T.; Moog, C.; Liljestrom, P.; Wagner, R.; Wolf, H.; Kraehenbuhl, J. P.; Esteban, M.; Heeney, J.; Frachette, M. J.; Tartaglia, J.; McCormack, S.; Babiker, A.; Weber, J.; Pantaleo, G. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 2008, 205, 63-77. (Pubitemid 351185716)
9. de Alencar, B. C. G.; Persechini, P. M.; Haolla, F. A.; de Oliveira, G.; Silverio, J. C.; Lannes-Vieira, J.; Machado, A. V.; Gazzinelli, R. T.; Bruna-Romero, O.; Rodrigues, M. M. Perforin and Gamma Interferon Expression Are Required for CD4(+) and CD8(+) T-Cell-Dependent Protective Immunity against a Human Parasite, Trypanosoma cruzi, Elicited by Heterologous Plasmid DNA Prime-Recombinant Adenovirus 5 Boost Vaccination. Infect. Immun. 2009, 77, 4383-4395.
10. Ishizaki, H.; Song, G. Y.; Srivastava, T.; Carroll, K. D.; Shahabi, V.; Manuel, E. R.; Diamond, D. J.; Ellenhorn, J. D. I. Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression. J. Immunother. 2010, 33, 609-617.
11. Estcourt, M. J.; Ramsay, A. J.; Brooks, A.; Thomson, S. A.; Medveckzy, C. J.; Ramshaw, I. A. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int. Immunol. 2002, 14, 31-37. (Pubitemid 34083395)
12. Masopust, D.; Ha, S. J.; Vezys, V.; Ahmed, R. Stimulation history dictates memory CD8 T cell phenotype: implications for primeboost vaccination. J. Immunol. 2006, 177, 831-839. (Pubitemid 44036583)
13. Schneider, J.; Gilbert, S. C.; Hannan, C. M.; Degano, P.; Prieur, E.; Sheu, E. G.; Plebanski, M.; Hill, A. V. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 1999, 170, 29-38. (Pubitemid 29490742)
14. Thorner, A. R.; Lemckert, A. A.; Goudsmit, J.; Lynch, D. M.; Ewald, B. A.; Denholtz, M.; Havenga, M. J.; Barouch, D. H. Immunogenicity of heterologous recombinant adenovirus primeboost vaccine regimens is enhanced by circumventing vector crossreactivity. J. Virol. 2006, 80, 12009-12016. (Pubitemid 44904350)
15. McShane, H.; Hill, A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 2005, 7, 962-967. (Pubitemid 40826666)
16. Bungener, L.; Huckriede, A.; de Mare, A.; Vries-Idema, J.; Wilschut, J.; Daemen, T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005, 23, 1232-1241. (Pubitemid 40126526)
17. Daemen, T.; de Mare, A.; Bungener, L.; de Jonge, J.; Huckriede, A.; Wilschut, J. Virosomes for antigen and DNA delivery. AdV. Drug DeliVery Rev. 2005, 57, 451-463. (Pubitemid 39550970)
18. Daemen, T.; Pries, F.; Bungener, L.; Kraak, M.; Regts, J.; Wilschut, J. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther. 2000, 7, 1859-1866.
19. Riezebos-Brilman, A.; de Mare, A.; Bungener, L.; Huckriede, A.; Wilschut, J.; Daemen, T. Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J. Clin. Virol. 2006, 35, 233-243. (Pubitemid 43188967)
20. Daemen, T.; Riezebos-Brilman, A.; Bungener, L.; Regts, J.; Dontje, B.; Wilschut, J. Eradication of established HPV16- transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 2003, 21, 1082-1088. (Pubitemid 36139938)
21. Daemen, T.; Riezebos-Brilman, A.; Regts, J.; Dontje, B.; van der Zee, A.; Wilschut, J. Superior therapeutic efficacy of alphavirusmediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. AntiViral Ther. 2004, 9, 733-742. (Pubitemid 39434337)
22. Bungener, L.; de Mare, A.; de Vries-Idema, J.; Sehr, P.; van der Zee, A.; Wilschut, J.; Daemen, T. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. AntiViral Ther. 2006, 11, 717-727. (Pubitemid 44497167)
23. Riezebos-Brilman, A.; Walczak, M.; Regts, J.; Rots, M.; Kamps, G.; Dontje, B.; Haisma, H.; Wilschut, J.; Daemen, T. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther. 2007, 14, 1695-1704. (Pubitemid 350238446)
24. Bron, R.; Ortiz, A.; Dijkstra, J.; Stegmann, T.; Wilschut, J. Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol. 1993, 220, 313-331.
25. Bungener, L.; Idema, J.; ter Veer, W.; Huckriede, A.; Daemen, T.; Wilschut, J. Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J. Liposome Res. 2002, 12, 155-163. (Pubitemid 34846968)
26. Liljestrom, P.; Garoff, H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N.Y.) 1991, 9, 1356-1361.
27. Berglund, P.; Sjoberg, M.; Garoff, H.; Atkins, G. J.; Sheahan, B. J.; Liljestrom, P. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N.Y.) 1993, 11, 916-920. (Pubitemid 23218980)
28. Chen, M.; Barnfield, C.; Naslund, T. I.; Fleeton, M. N.; Liljestrom, P. MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J. Virol. 2005, 79, 2964-2972. (Pubitemid 40270575)
29. Huckriede, A.; Bungener, L.; Holtrop, M.; de Vries, J.; Waarts, B. L.; Daemen, T.; Wilschut, J. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 2004, 22, 1104-1113. (Pubitemid 38296652)
30. Daemen, T.; Regts, J.; Holtrop, M.; Wilschut, J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 2002, 9, 85-94. (Pubitemid 34189523)
31. Smerdou, C.; Liljestrom, P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J. Virol. 1999, 73, 1092-1098. (Pubitemid 29036760)
32. Smits, P. H.; Smits, H. L.; Jebbink, M. F.; ter Schegget, J. The short arm of chromosome 11 likely is involved in the regulation of the human papillomavirus type 16 early enhancer-promoter and in the suppression of the transforming activity of the viral DNA. Virology 1990, 176, 158-165. (Pubitemid 20149678)
33. Fiedler, M.; Campo-Fernandez, B.; Laich, A.; Moser, B.; Stockl, P.; Jansen-Durr, P.; Zwerschke, W. Purification and characterisation of the E7 oncoproteins of the high-risk human papillomavirus types 16 and 18. J. Virol. Methods 2006, 134, 30-35.
34. Mannhardt, B.; Weinzimer, S. A.; Wagner, M.; Fiedler, M.; Cohen, P.; Jansen-Durr, P.; Zwerschke, W. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulinlike growth factor binding protein 3. Mol. Cell. Biol. 2000, 20, 6483-6495. (Pubitemid 30650235)
35. Bachmann, M. F.; Wolint, P.; Schwarz, K.; Jager, P.; Oxenius, A. Functional properties and lineage relationship of CD8(+) T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J. Immunol. 2005, 175, 4686-4696. (Pubitemid 41362010)
36. He, H.; Wisner, P.; Yang, G. J.; Hu, H. M.; Haley, D.; Miller, W.; O'Hara, A.; Alvord, W. G.; Clegg, C. H.; Fox, B. A.; Urba, W. J.; Walker, E. B. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J. Transl. Med. 2006, 4.
37. McMichael, A. J.; Hanke, T. HIV vaccines 19832003. Nat. Med. 2003, 9, 874-880. (Pubitemid 36889929)
38. Sharpe, S.; Polyanskaya, N.; Dennis, M.; Sutter, G.; Hanke, T.; Erfle, V.; Hirsch, V.; Cranage, M. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 2001, 82, 2215-2223. (Pubitemid 32827602)
39. Sumida, S. M.; Truitt, D. M.; Kishko, M. G.; Arthur, J. C.; Jackson, S. S.; Gorgone, D. A.; Lifton, M. A.; Koudstaal, W.; Pau, M. G.; Kostense, S.; Havenga, M. J.; Goudsmit, J.; Letvin, N. L.; Barouch, D. H. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 2004, 78, 2666-2673. (Pubitemid 38314325)
40. Sundback, M.; Douagi, I.; Dayaraj, C.; Forsell, M. N.; Nordstrom, E. K.; McInerney, G. M.; Spangberg, K.; Tjader, L.; Bonin, E.; Sundstrom, M.; Liljestrom, P.; Karlsson Hedestam, G. B. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Virology 2005, 341, 190-202. (Pubitemid 41416729)
41. de Mare, A.; Lambeck, A. J. A.; Regts, J.; van Dam, G. M.; Nijman, H. W.; Snippe, H.; Wilschut, J.; Daemen, T. Viral vectorbased prime-boost immunization regimens: a possible involvement of T-cell competition. Gene Ther. 2008, 15, 393-403. (Pubitemid 351330997)
42. Lambeck, A. J. A.; Nijman, H. W.; Hoogeboom, B. N.; Regts, J.; de Mare, A.; Wilschut, J.; Daemen, T. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine 2010, 28, 4275-4282.
43. Apostolou, I.; von, B. H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 2004, 199, 1401-1408. (Pubitemid 38685731)
44. Banerjee, D. K.; Dhodapkar, M. V.; Matayeva, E.; Steinman, R. M.; Dhodapkar, K. M. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006, 108, 2655-2661.
45. Berraondo, P.; Nouze, C.; Preville, X.; Ladant, D.; Leclerc, C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res. 2007, 67, 8847-8855. (Pubitemid 47437461)
46. Dahlberg, P. E.; Schartner, J. M.; Timmel, A.; Seroogy, C. M. Daily subcutaneous injections of peptide induce CD4+ CD25+ T regulatory cells. Clin. Exp. Immunol. 2007, 149, 226-234. (Pubitemid 47063044)
47. Hussain, S. F.; Paterson, Y. CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 2004, 27, 339-346. (Pubitemid 39121922)
48. Maksimow, M.; Miiluniemi, M.; Marttila-Ichihara, F.; Jalkanen, S.; Hanninen, A. Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood 2006, 108, 1298-1305. (Pubitemid 44232028)
49. Silver, P. B.; Agarwal, R. K.; Su, S. B.; Suffia, I.; Grajewski, R. S.; Luger, D.; Chan, C. C.; Mahdi, R. M.; Nickerson, J. M.; Caspi, R. R. Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J. Immunol. 2007, 179, 5146-5158.
50. Zhou, G.; Drake, C. G.; Levitsky, H. I. Amplification of tumorspecific regulatory T cells following therapeutic cancer vaccines. Blood 2006, 107, 628-636. (Pubitemid 43076387)
51. Hovav, A. H.; Cayabyab, M. J.; Panas, M. W.; Santra, S.; Greenland, J.; Geiben, R.; Haynes, B. F.; Jacobs, W. R.; Letvin, N. L. Rapid memory CD8(+) T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis. J. Virol. 2007, 81, 74-83. (Pubitemid 44975148)
52. Huster, K. M.; Busch, V.; Schiemann, M.; Linkemann, K.; Kerksiek, K. M.; Wagner, H.; Busch, D. H. Selective expression of IL-7 receptor on memory T cells identifies early CD40Ldependent generation of distinct CD8(+) memory T cell subsets. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5610-5615. (Pubitemid 38481204)
53. Radcliffe, J. N.; Roddick, J. S.; Friedmann, P. S.; Stevenson, F. K.; Thirdborough, S. M. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8(+) T cells. J. Immunol. 2006, 177, 6626-6633. (Pubitemid 44715025)
54. Bungener, L.; Serre, K.; Bijl, L.; Leserman, L.; Wilschut, J.; Daemen, T.; Machy, P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002, 20, 2287-2295. (Pubitemid 34497039)
55. La Gruta, N. L.; Kedzierska, K.; Pang, K.; Webby, R.; Davenport, M.; Chen, W.; Turner, S. J.; Doherty, P. C. A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 994-999. (Pubitemid 43212210)
56. Li, S.; Rodrigues, M.; Rodriguez, D.; Rodriguez, J. R.; Esteban, M.; Palese, P.; Nussenzweig, R. S.; Zavala, F. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. U.S.A 1993, 90, 5214-5218. (Pubitemid 23183008)
57. van der Burg, S. H.; Kwappenberg, K. M.; O'Neill, T.; Brandt, R. M.; Melief, C. J.; Hickling, J. K.; Offringa, R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous primeboost regimens. Vaccine 2001, 19, 3652-3660. (Pubitemid 32522763)
58. Ali, S.; Mulryan, K.; Taher, T.; Stern, P. L. Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen. Cancer Immunol. Immunother. 2007, 56, 165-180. (Pubitemid 44833091)
59. Monsurro, V.; Wang, E.; Yamano, Y.; Migueles, S. A.; Panelli, M. C.; Smith, K.; Nagorsen, D.; Connors, M.; Jacobson, S.; Marincola, F. M. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004, 104, 1970-1978. (Pubitemid 39297845)
60. Wherry, E. J.; Teichgraber, V.; Becker, T. C.; Masopust, D.; Kaech, S. M.; Antia, R.; von Andrian, U. H.; Ahmed, R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 2003, 4, 225-234. (Pubitemid 36322131)
61. Ahlers, J. D.; Belyakov, I. M. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010, 115, 1678-1689.
62. Harrington, L. E.; Most Rv, R.; Whitton, J. L.; Ahmed, R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 2002, 76, 3329-3337. (Pubitemid 34224535)
63. Tsai, V.; Johnson, D. E.; Rahman, A.; Wen, S. F.; LaFace, D.; Philopena, J.; Nery, J.; Zepeda, M.; Maneval, D. C.; Demers, G. W.; Ralston, R. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin. Cancer Res. 2004, 10, 7199-7206. (Pubitemid 39487706)
64. Lowenstein, P. R. Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects. Mol. Ther. 2004, 9, 771-774. (Pubitemid 38878123)
65. Lauterbach, H.; Ried, C.; Epstein, A. L.; Marconi, P.; Brocker, T. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J. Gen. Virol. 2005, 86, 2401-2410. (Pubitemid 41167587)
66. Manno, C. S.; Pierce, G. F.; Arruda, V. R.; Glader, B.; Ragni, M.; Rasko, J. J.; Ozelo, M. C.; Hoots, K.; Blatt, P.; Konkle, B.; Dake, M.; Kaye, R.; Razavi, M.; Zajko, A.; Zehnder, J.; Rustagi, P. K.; Nakai, H.; Chew, A.; Leonard, D.; Wright, J. F.; Lessard, R. R.; Sommer, J. M.; Tigges, M.; Sabatino, D.; Luk, A.; Jiang, H.; Mingozzi, F.; Couto, L.; Ertl, H. C.; High, K. A.; Kay, M. A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12, 342-347. (Pubitemid 43355084)
67. Chen, J.; Wu, Q.; Yang, P.; Hsu, H. C.; Mountz, J. D. Determination of specific CD4 and CD8 T cell epitopes after. Mol. Ther. 2006, 13, 260-269.
68. Nilsson, C.; Makitalo, B.; Berglund, P.; Bex, F.; Liljestrom, P.; Sutter, G.; Erfle, V.; ten Haaft, P.; Heeney, J.; Biberfeld, G.; Thorstensson, R. Enhanced simian immunodeficiency virusspecific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 2001, 19, 3526-3536. (Pubitemid 32710305)
69. Palmowski, M. J.; Choi, E. M.; Hermans, I. F.; Gilbert, S. C.; Chen, J. L.; Gileadi, U.; Salio, M.; Van Pel, A.; Man, S.; Bonin, E.; Liljestrom, P.; Dunbar, P. R.; Cerundolo, V. Competition between CTL narrows the immune response induced by primeboost vaccination protocols. J. Immunol. 2002, 168, 4391-4398. (Pubitemid 34441339)
70. Rollier, C.; Verschoor, E. J.; Paranhos-Baccala, G.; Drexhage, J. A.; Verstrepen, B. E.; Berland, J. L.; Himoudi, N.; Barnfield, C.; Liljestrom, P.; Lasarte, J. J.; Ruiz, J.; Inchauspe, G.; Heeney, J. L. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J. Infect. Dis. 2005, 192, 920-929. (Pubitemid 41193091)